Skip to main content


  • Research article
  • Open Access
  • Open Peer Review

High-resolution SNP array analysis of patients with developmental disorder and normal array CGH results

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 1, 5, 7,
  • 6, 7,
  • 7,
  • 8,
  • 3,
  • 9,
  • 10,
  • 7 and
  • 1
BMC Medical Genetics201213:84

  • Received: 30 May 2011
  • Accepted: 5 September 2012
  • Published:

The Erratum to this article has been published in BMC Medical Genetics 2014 15:124

Open Peer Review reports



Diagnostic analysis of patients with developmental disorders has improved over recent years largely due to the use of microarray technology. Array methods that facilitate copy number analysis have enabled the diagnosis of up to 20% more patients with previously normal karyotyping results. A substantial number of patients remain undiagnosed, however.

Methods and Results

Using the Genome-Wide Human SNP array 6.0, we analyzed 35 patients with a developmental disorder of unknown cause and normal array comparative genomic hybridization (array CGH) results, in order to characterize previously undefined genomic aberrations. We detected no seemingly pathogenic copy number aberrations. Most of the vast amount of data produced by the array was polymorphic and non-informative. Filtering of this data, based on copy number variant (CNV) population frequencies as well as phenotypically relevant genes, enabled pinpointing regions of allelic homozygosity that included candidate genes correlating to the phenotypic features in four patients, but results could not be confirmed.


In this study, the use of an ultra high-resolution SNP array did not contribute to further diagnose patients with developmental disorders of unknown cause. The statistical power of these results is limited by the small size of the patient cohort, and interpretation of these negative results can only be applied to the patients studied here. We present the results of our study and the recurrence of clustered allelic homozygosity present in this material, as detected by the SNP 6.0 array.


  • Developmental disorder
  • SNP array
  • Diagnostic yield


The diagnostic yield of microarray comparative genomic hybridizations (array CGH) has already proven to exceed that of cytogenetic methods, except when it comes to balanced rearrangements. A consensus statement suggests that microarrays should be used as the first line of testing for developmental disorders of unknown cause [1]. However, as our previous study shows, approximately 80 % of patients with a developmental disorder of unknown cause (mental retardation and/or malformations and/or neurological disorders) remain undiagnosed even by array CGH analysis (44 K, 180 K, or 244 K) [2]. Thus, other methods are clearly needed to define the pathogenic mechanisms. It is plausible that small copy number variants (CNVs) may go undetected if the probe coverage is limited, as it may be in low-resolution arrays. By increasing the resolution, one would thus expect to detect increasingly smaller pathogenic CNVs.

The frequency of uniparental disomy (UPD) in newborns is reportedly ~0.029% [3]. Around 1,100 cases of whole chromosome UPD and some 120 reports on segmental UPD are described in the literature [4]. Some recessive diseases are expressed in children who have inherited the mutation form a single carrier parent [5]. The explanation for this is a meiotic or very early mitotic recombination event between parental homologous chromosomes causing segmental UPD of the genomic segment containing the mutation, and thereby causing a reduction to homozygosity.

As the market is flooded with new arrays, most having an increased resolution and a promise of ever higher detection rates, the question remains what the added value is of these ultra-high resolution arrays. To test this, we used an array with 1.8 million probes and an average resolution of 0.7Kb to analyze samples of 35 patients with developmental disorder of unknown cause, normal karyotype, and normal array CGH results by use of Agilent 44 K, 180 K, or 244 K platforms (Agilent Technologies, Santa Clara, CA, USA).



Patients with previous normal array CGH results were asked to participate in the project. All 35 patients were Finnish of origin and had mild to severe mental retardation, associated with dysmorphic features and/or congenital anomalies (Table 1). In addition, 16 patients also had epilepsy. For diagnostic purposes patients had previously been analyzed by whole-genome array CGH (Human Genome CGH Microarray, Agilent Technologies, Santa Clara, CA); 20 using the 244 K platform, 8 using a 180 K platform, and 7 using a 44 K platform. Informed consent was given by all participating families. Blood samples were collected from all patients and their parents. Ethical permission for this project was given by the Ethics Review Board of Helsinki and Uusimaa Hospital District.
Table 1

Clinical characteristics of patients studied

P. Nr.


Head and neck

Eyes and vision

Ears and hearing




Skeletal and limb defects








Postaxial polydactyly (one foot) Short meta-carpals V finger clino-dactyly

ID Hypotonia

Bardet-Biedl suspected



Severe DD No walk/crawl No speech Epilepsy Drooling




Dolicocephaly Narrow, prominent forehead Low, uneven hairline

Epichantal folds


DD Abnormal pons



Short stature


Low nasal bridge


Horseshoe kidney Anal atresia

Small hands and feet


Balanced t(X;13)(q28;q12)



Simple ears

Thick and straight eyebrows Broad nasal bridge Long philtrum Retrognathia


Autism ID Epilepsy



Short stature


Blindness Optic nerve hypoplasia



ID Epilepsy Severe hypotonia






Brain malformation Severe DD







Small nose Low nasal bridge Tented upper lip


Severe DD Severe epilepsy

ATRX suspected



Severe optic atrophy Impaired vision


ID Epilepsy Cortical atrophy




Mild hypertelorism

Low-set ears

Triangular face Small jaw High palate Thin upper lip


Hyper-extensible joints

ID Autistic features Intractable epilepsy

Frax-dna, SCN1A, CLN8 4p-FISH normal



Upslanting palpebal fissures

Large earlobes

Small jaw



ID Autistic features Intractable epilepsy




Epichantic folds

Large earlobes

Flat face


Tapering fingers

ID Autistic features ADHD

Balanced t(2;9)(q13q22.3) de novo





Severe ID Hypotonia Autism Epilepsy

Inv 2(p13p25) mat., DMPK mutation negative



Severe myopia Cataracta


Synophrys Curved eyebrows Upturned pinched nose Big mouth Full lips

Atrial septum defect


Severe DD Epilepsy





Impaired vision


Ventricular septum defect


Epilepsy DD




ID Beahvioural disturbances Autism

No malformation or dysmorphism






Growth retardation




Mild ventricular septum defect




19. & 20.



No structural defects





Missing lobuli

Small nose Low nasal bridge Smooth philtrum Thin lips


Proximal thumbs Pes planus

ID Intractable epilepsy Ataxia



Pre- and postnatal growth retardation


Broad nasal root Short nose Bifid nasal tip


Cryptorchidism Hypoplastic scrotum

Scoliosis Syndactylies

Slow motor development Hypotonia Expressive language disorder

Congenital contractures Dimples



Mild dysmorphism


ID Epilepsy





Hypertelorism Epicanthic folds Disorder of visual cortex

Low-set and posteriorly rotated ears

Micrognathia Cleft palate


ID Epilepsy Hypoplastic cerebellar vermis

Monozygotic twin, twin sister healthy


Tall stature Advanced bone age


Deep set eyes Hypotelorism Epicanthic folds Strabismus


Short nose Anteverted nares Tented upper lip




ID No speech Autism

Glypican-3 and PHF6 mutation analyses negative


Short stature


ID Intractable epilepsy Tremor Myoclonias Distal spasticity



Small for Gestational Age


Downslanting palpebral fissures Strabismus


Frontal bossing


Exostosis (familial) Broad hallux Overriding toes Scoliosis

ID Epilepsy

Inguinal hernia



Downslanting palpebral fissures

Hearing impairment

Coarse hair Thick eyebrows Thick lips Malposition of teeth

Hypertrophic cardiomyopathy


Hip dis-placement Long thin bones

Normal intelligence




Epilepsy ID Alternating hemiplegia of childhood



Small for gestational age Prematurity Short stature


Severe myopia Coloboma of papillae Optic atrophy Nystagmus Strabismus


High palate Gum hypertrophy

Coarctation of aorta

Inguinal hernia


ID Intractable epilepsy Hemiparesis (peri-ventricular leukomalacia)




Central blindness Nystagmus


ID Intractable epilepsy Hypotonia Distal spasticity



Short stature


Normal development

Vomiting Feeding difficulties



Neck fistula


Dysmorphic malocclusion of teeth

Uni-ventricular heart


Brain atrophy Epilepsy

Simian-crease Sinus pilonidalis



ID Intractable epilepsy Hypotonia Distal spasticity





Epichantic fold

Simple ears

Thin upper-lip Long philtrum Broad nasal bridge


ID Arnold Chiari malformation


The table presents the clinical characteristics of the 35 patients studied. DD = developmental delay, ID = intellectual disability.

SNP array

DNA was extracted from blood samples according to standard protocols. Analysis by the Genome-wide human SNP array 6.0 was performed according to manufacturer protocols (Affymetrix, Santa Clara, CA, USA). In short; DNA was digested, ligated to adapters, and amplified by PCR. Samples were purified using magnetic beads and further fragmented and labelled with biotin. After hybridization arrays were washed and stained with streptavidin and anti-streptavidin antibodies and finally the arrays were scanned using the Affymetrix GeneChip scanner.


Data was extracted from the scanned image using the Genotyping console software V.3.0.2, creating a CEL file. Areas containing CNVs and allelic homozygosity were detected using the Hidden-Markow-Model. The resulting data was analyzed using the Chromosome Analysis Suite software V.1.0.

Reference data

Data was extracted by comparison to a reference data set established from 90 Caucasian individuals, which had previously been analyzed using the SNP 6.0 array in the HapMap project ( As an additional in-house reference set, we used results of 54 individuals studied using the SNP 6.0 array, whereof 19 healthy normal relatives of the patients, and 35 unrelated patients with an unexplained developmental disorder. Sample identities were kept anonymous and the information was only used for reference purposes. These in-house reference sets were used to filter out polymorphic changes in the patient data studied here.

Selected CNVs of the patients were compared to a Finnish population cohort [6]. This population cohort data consist of CNVs detected, using whole-genome SNP analysis, in 2163 healthy Finnish individuals with PennCNV [7]. In the population data, low quality samples (N = 98) with Log R Ratio standard deviation of probe signal intensities > 0.35 or > 115 CNV calls were excluded. Only CNVs with three or more probes were included in the final population data. CNV calls of the study samples were clustered into CNV regions when individual CNVs overlapped by one or more base pairs.

Filtering relevant CNVs and potential UPDs

The first set of default filtering marked all duplications and deletions ≥0.7Kb and all allelic homozygosities ≥100Kb containing at least 10 markers to be included. This was based on the theoretical resolution of the array being 0.7Kb, in addition to information from the HapMap phase 1 study showing that approximately 70% of common haplotype blocks are ≤100Kb [8] . Allelic homozygosity was called by the analysis software where there was a stretch of homozygous SNPs in a chromosomal segment.

The second filtering was based on the comparison of all aberrations detected in the patients of this study (N = 35), an in-house patient reference set (N = 35) and an in-house normal reference set (N = 19) as well as the database of genomic variants (DGV) [9]. Aberrations of one patient that were not present in any of the other groups (potentially “unique”) were further processed by studying their genetic content and association to diseases and traits, as stated in publications or OMIM, and whether these correlated to the patient’s phenotype. If this did not yield a candidate aberration, all aberrations of a patient were reviewed based on only the associated OMIM disease, despite the frequency of similar changes in the reference sets. The CNVs that were picked out as potential candidates were further compared to CNV data from 2,065 healthy Finnish individuals. Only those aberrations that were present in less than 50 individuals of the Finnish population cohort were initially considered as potentially pathogenic.

Validation of candidate aberrations

Only aberrations that were considered to potentially associate with patient’s phenotype were attempted validation.

Microsatellite marker analysis

Potential segmental UPDs were analyzed by microsatellite marker analysis (chr15: D15S204, D15S124; chr6: D6S468, D6S2418; chr11: D11S4140; chr17: D17S578, D17S1832, D17S1828).

The markers were selected based on their location, and on information that they are highly polymorphic in the Caucasian population. Fragments were labelled with a fluorescent HEX label, and separated on an Applied Biosystem 3730XL (Life Technologies, Carlsbad, CA, USA) capillary electrophoresis instrument, according to manufacturer recommendations. Genotypes were called using Applied Biosystems GeneMapper 3.7 software.


The immense amount of data created by the Genome-wide human SNP array 6.0 warrants filtering for clear interpretation. The Genotyping Console software identified between 200–1000 changes per patient (Figure 1), depending on the technical quality of the result. More changes were detected in samples with lesser quality. After filtering, based on the uniqueness of the CNVs or regions of homozygosity compared to the references, each patient presented 8–20 unique changes (≥90% CNVs) on average. In samples with lesser quality, ≥100 unique changes were detected. Further research on gene content and phenotypes previously mapped to these regions revealed 23 CNVs and 28 regions of homozygosity that putatively correlated with the clinical phenotype in 26 patients. Nine patients had no CNVs or regions of homozygosity spanning known genes or genes known to associate with a disease that correlated with the patient’s phenotype, and their results were thus considered normal. The associated phenotypes related to the aberration found in 26 patients were further evaluated by the patients’ clinicians, and the frequencies of the observed CNVs were monitored in the Finnish population cohort (n = 2,065). As a result, in four patients, a region of allelic homozygosity was considered a potential candidate for causation of their clinical state (Table 2). No CNVs were considered candidates after clinical evaluation.
Figure 1
Figure 1

Frequency of CNVs and allelic homozygosity. The figure visualizes the frequency of copy number changes (loss and gain) and regions of allelic homozygosity (LOH) in 70 patients (patients of this study N = 35 and the in-house reference set N = 35) with developmental disorders of unknown cause as seen by the Integrative Genomics Viewer (IGV) software V.1.5 (The Broad Institute, Cambridge, MA, USA). The vertical bars show the percentage of patients that have a CNV in a particular area of a chromsome. The higher the bar, the higher the percentage, thus indicating as CNP.

Table 2

Results from microsatellite marker analysis


Chromosome location


Location start

Location stop




Associated OMIM disease (gene)









MIM #209900, Bardet-Biedl Syndrome (BBS4)

















MIM #611092, Mental retardation (GRIK2)

















MIM #270400, Smith-Lemli-Opitz syndrome (DHCR7)









MIM #201475, AcylCoA dehydrogenase deficiency (ACADVL)
















The table presents the results of microsatellite marker analysis of 4 patients and their parents, suggesting biparental inheritance of the genomic segment, and thus exclude segmental UPD. The numbers in the patient/mother/father column represent the two markers detected. In all cases, the patient has likely inherited one marker from each parent.

We further attempted verification of four potential segmental UPDs by microsatellite marker analysis. In all the four cases we observed two distinct alleles with at least some of the more informative multiallelic markers, suggesting that the observed LOHs were most probably caused by the same allelic SNP haplotypes being inherited from both the parents (Table 2).

Further comparison, of all patient SNP array data to the normal data from unaffected individuals, revealed 21 regions of clustering (≥40 % frequency) of allelic homozygosity to specific locations of the genome (Table 3). However, no significant differences were detected between the frequencies of clustered regions in patients and the unaffected relatives in this small set of samples.
Table 3

Regions of clustered allelic homozygosity



Appoximate range (Kb)

Frequency patients (n = 70)

Frequency normals (n = 19)



48 700–53 300





145 800–148 500





134 334–136 693





46 500–52 500





31 838–34 524





99 200–101 200





41 870–43 270





47 040–49 000





36 720–38 490





73 200–76 460





85 850–89 100





108 600–111 600





65 500–67 100





25 400–27 200





40 100–43 730





69 300–71 700





33 394–34 550





45 092–47 450





64 850–67 100





54 610–56 850





31 910–35 500



The table presents the frequency (> 40%) of clustered regions of allelic homozygosity in the patient cohort (n = 70, including in-house reference) compared to the unaffected relatives (n = 19). Kilobase range according to Genome build 19 (NCBI 37).


In our previous study of 150 patients with developmental disorders of unknown cause and a normal karyotype, we were able to identify a (potential) causative aberration in 18% of the patients, by using a 44 K or 244 K array CGH platform [2].

To determine whether, by increasing the resolution, any additional copy number changes or regions of UPD could be detected, we studied 35 patients with a normal array CGH result.

Allelic homozygosity is typically caused by linkage and co-segregation of certain blocks of DNA, termed haplotypes [8]. In a small founder population, such as the Finnish population, the founder effect increases the likelihood that the parents will have the same haplotype, and is as such not a segmental UPD [10]. True segmental UPD is typically due to a duplication in one chromosome and a reciprocal deletion in the other; or the fertilization of a disomic and monosomic gamete, somatic crossing over and subsequent trisomic rescue [11]. If the genomic segment harbours a recessive mutation, which subsequent to UPD will be present in two copies (reduction to homozygosity), it causes a recessive disease. Equally relevant, the segment can be preferentially imprinted, causing complete silencing, which is the equivalent of a deletion. Such presentations of recessive syndromes that are inherited from one normal parent are known in some 40 patients [12].

We were interested to see whether the regions of allelic homozygosity detected by the SNP array were in fact segmental UPDs and associated with an autosomal recessive disease. We were, however, unable to confirm these results and thus the SNP array did not yield more molecular diagnoses in this study of developmental disorders of unknown cause. This may be due to the fact that all patients had previously been studied by another high-resolution array, with 8.9Kb (244 K), 13Kb (180 K), and 35Kb (44 K) theoretical resolutions. Although several new CNVs, previously undetected by the array CGH platform, as well as regions of homozygosity were detected, the pathogenic relevance of these changes were considered insignificant in correlation to the patient’s phenotype. It is, however, possible that changes dismissed in this study are pathogenic by means of spanning genomic segments that do not directly involve disease genes, but rather their regulatory elements.

Our results differ from previously published studies using similar research settings. Bernardini et al. (2010), using the SNP 6.0 array platform with a 75Kb cut-off value for detected CNVs, reported potentially pathogenic CNVs in 6% of patients with normal array CGH result (44 K) [13]. Mannik et al. (2010), using another SNP array with a 50Kb resolution, reported a 23% detection rate in patients with a normal karyotype [14]. Bernardini et al. and Mannik et al. had higher detection rates than this study; perhaps as their first-line of array analysis was, at least partly, done by a lower-resolution method (35Kb and 50Kb respectively) compared to the first-line of detection in this study (8,9Kb, 13Kb and 35Kb). Also, it is important to note that the statistical power is limited by the small size of our patient cohort, and thus results are not entirely comparable with Bernardini and Mannik’s.

UPDs have not been reported in either of the above mentioned studies. However, in a study of 117 patients with a normal karyotype analysed using the 250 K SNP array (Affymetrix, Santa Clara, CA, USA), pathogenic CNVs were detected in 18 patients, and potentially pathogenic segmental UPDs ≥5 Mb in 5, verified by microsatellite marker analysis [15]. The presence of UPDs was also evaluated in another study of 120 patients, using a 500 K SNP array platform [16]. In that study they were unable to verify UPD in any of 121 detected regions of homozygosity in 72 patients with developmental disorder of unknown cause. In addition, in a study of 100 patients with developmental disorder, using a 500 K SNP array, two patients were found to have UPD, the clinical significance of which remained unclear [17]. Thus, UPDs are detectable using SNP arrays, but their clinical significance is difficult to interpret.


Although there is a clear added value of high-resolution arrays in various fields of genetics, it seems that there is a limit to how much the yield can be increased by increasing the theoretical resolution of the analysis platform. Despite the fact that the SNP array has increased probe spacing compared to the 44 K, 180 K, and 244 K array, and is able to detect more CNVs and regions of homozygosity, interpretation of the vast amount of data and pinpointing of pathogenic changes is difficult. One benefit of using a SNP based platform is the possibility to detect UPDs; however these are relatively rare findings.

This study had a limited number of patients, and so it can only be said that for this study group the optimal yield was conceived when using a resolution of approximately 9Kb [2]. Increasing the resolution beyond that did not confer more diagnoses. It must be emphasized, however, that a larger patient cohort needs to be studied in order to draw final conclusions on the added value of an ultra-high resolution array compared to others. Furthermore, as several reports have shown, some pathogenic aberrations span only a few exons and for detecting such small changes the sensitivity of the SNP 6.0 platform is adequate [18]. It is, however a challenge to filter results correctly and so for diagnostic purposes the choice of platform needs to be carefully considered. Patients with developmental disorders of unknown cause and normal array results may also harbour such small genomic changes (i.e. mutations and unbalanced rearrangements) that are difficult to interpret using microarrays and would require higher resolution methods, such as whole-exome sequencing. Interestingly, a recent study suggests that 80% of patients with a developmental disorder of unknown cause and normal array results can be diagnosed using whole-exome sequencing [19]. Only the future can tell.

Availability of supporting data

The data set supporting the results of this article is available in the CanGEM repository,




We thank all the participating patients and their families. A thanks to Marketta Dalla Valle for her contribution of clinical information. The staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute is acknowledged for genotyping of the Health 2000 study sample. This study was kindly supported by Rinnekoti Research Foundation, Medicinska Understödsföreningen Liv och Hälsa rf., and The Helsinki and Uusimaa Hospital District State Appropriations. K.K. was supported by the Orion-Farmos Research Foundation and the Academy of Finland (grant no. 125973).

Authors’ Affiliations

Department of Pathology, Haartman Institute, University of Helsinki, and Laboratory of Helsinki and Uusimaa University Hospital, Helsinki, Finland
Rinnekoti Foundation, Rehabilitation Home for Children, Espoo, Finland
Department of Pediatric Neurology, Helsinki University Central Hospital, Helsinki, Finland
Väestöliitto, The Family Federation of Finland, Department of Medical Genetics, Helsinki, Finland
Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
Public Health Genomics Unit, Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
Institute for Molecular Medicine Finland FIMM, University Helsinki, Helsinki, Finland
Department of Clinical Genetics, Turku University Hospital and Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland
Department of Pediatrics, Satakunta Hospital District, Pori, Finland
Population Health Unit, Department of Health, Functional Capacity and Welfare, National Institute for Health and Welfare, P.O. Box 21, 00014 Helsinki, Finland


  1. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin LC, Ledbetter DH: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010, 86: 749-764. 10.1016/j.ajhg.2010.04.006.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Siggberg L, Ala-Mello S, Jaakkola E, Kuusinen E, Schuit R, Kohlhase J, Bohm D, Ihnatius J, Knuutila S: Array CGH in molecular diagnosis of mental retardation - A study of 150 Finnish patients. Am J Med Genet A. 2010, 152A: 1398-1410.PubMedGoogle Scholar
  3. Robinson WP: Mechanisms leading to uniparental disomy and their clinical consequences. BioEssays. 2000, 22: 52-459.View ArticleGoogle Scholar
  4. Liehr T: Cytogenetic contribution to uniparental disomy (UPD). Mol Cytogenet. 2010, 3: 8-10.1186/1755-8166-3-8.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Kotzot D: Complex and segmental uniparental disomy updated. J Med Genet. 2008, 45: 545-556. 10.1136/jmg.2008.058016.View ArticlePubMedGoogle Scholar
  6. Health: THL - National Institute for Health and Welfare. 2000, Accessed 30.8.2010, 2010, at Google Scholar
  7. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M: PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007, 17: 1665-1674. 10.1101/gr.6861907.View ArticlePubMedPubMed CentralGoogle Scholar
  8. International HapMap Consortium: A haplotype map of the human genome. Nature. 2005, 437: 1299-1320. 10.1038/nature04226.View ArticleGoogle Scholar
  9. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Sherer SW, Lee C: Detection of large-scale variation in the human genome. Nat Genet. 2004, 36: 949-951. 10.1038/ng1416.View ArticlePubMedGoogle Scholar
  10. Kristiansson K, Naukkarinen J, Peltonen L: Isolated populations and complex disease gene identification. Genome Biol. 2008, 9: 109-10.1186/gb-2008-9-8-109.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Conlin LK, Thiel BD, Bonnemann CG, Medne L, Ernst LM, Zackai EH, Deardorff MA, Krantz ID, Hakonarson H, Spinner NB: Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis. Hum Mol Genet. 2010, 19: 1263-1275. 10.1093/hmg/ddq003.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Engel E: A fascination with chromosome rescue in uniparental disomy: Mendelian recessive outlaws and imprinting copyrights infringements. Eur J Hum Genet. 2006, 14: 1158-1169. 10.1038/sj.ejhg.5201619.View ArticlePubMedGoogle Scholar
  13. Bernardini L, Alesi V, Loddo S, Novelli A, Bottillo I, Battaglia A, Digilio MC, Zampino G, Ertel A, Fortina P, Surrey S, Dallapiccola B: High-resolution SNP arrays in mental retardation diagnostics: how much do we gain?. Eur J Hum Genet. 2010, 18: 178-185. 10.1038/ejhg.2009.154.View ArticlePubMedGoogle Scholar
  14. Mannik K, Parkel S, Palta P, Zilina O, Puusepp H, Esko T, Magi R, Noukas M, Veidenberg A, Nelis M, Metspalu A, Remm M, Ounap K, Kurg A: A parallel SNP array study of genomic aberrations associated with mental retardation in patients and general population in Estonia. Eur J Med Genet. 2011, 54: 136-143. 10.1016/j.ejmg.2010.11.005.View ArticlePubMedGoogle Scholar
  15. Bruno DL, Ganesamoorthy D, Schoumans J, Bankier A, Coman D, Delatycki M, Gardner RJ, Hunter M, James PA, Kannu P, McGilivray G, Pachter N, Peters H, Rieubland C, Savarirayan R, Scheffer IE, Sheffield L, Tan T, White SM, Yeung A, Bowman Z, Ngo C, Choy KW, Cacheux V, Wong L, Amor DJ, Slater HR: Detection of cryptic pathogenic copy number variations and constitutional loss of heterozygosity using high resolution SNP microarray analysis in 117 patients referred for cytogenetic analysis and impact on clinical practice. J Med Genet. 2009, 6: 123-131.Google Scholar
  16. McMullan DJ, Bonin M, Hehir-Kwa JY, de Vries BB, Dufke A, Rattenberry E, Steehouwer M, Moruz L, Pfundt R, de Leeuw N, Riess A, Altug-Teber O, Enders H, Singer S, Grasshof U, Walter M, Walker JM, Lamb CV, Davison EV, Bruetin L, Riess O, Veltman JA: Molecular karyotyping of patients with unexplained mental retardation by SNP arrays: a multicenter study. Hum Mutat. 2009, 30: 1082-1092. 10.1002/humu.21015.View ArticlePubMedGoogle Scholar
  17. Friedman J, Adam S, Arbour L, Armstrong L, Baross A, Birch P, Boerkoel C, Chan S, Chai D, Delaney AD, Flibotte S, Gibson WT, Langlois S, Lemyre E, Li HI, MacLeod P, Mathers J, Michaud JL, McGillivray BC, Patel MS, Qian H, Rouleau GA, Van Allen MI, Yong SL, Zahir FR, Eydoux P, Marra MA: Detection of pathogenic copy number variants in children with idiopathic intellectual disability using 500 K SNP array genomic hybridization. BMC Genomics. 2009, 10: 526-10.1186/1471-2164-10-526.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Behnecke A, Hinderhofer K, Bartsch O, Nümann A, Ipach ML, Damatova N, Haaf T, Dufke A, Riess O, Moog U: Intragenic deletions of IL1RAPL1: Report of two cases and review of the literature. Am J Med Genet A. 2011, 155A: 372-379.View ArticlePubMedGoogle Scholar
  19. Vissers LE, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P, van Lier B, Arts P, Wieskamp N, del Rosario M, van Bon BW, Hoischen A, de Vries BB, Bruner HG, Veltman JA: A de novo paradigm for mental retardation. Nat Genet. 2010, 42: 1109-1112. 10.1038/ng.712.View ArticlePubMedGoogle Scholar
  20. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:


© Siggberg et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.